Key Performance Indicators 2011
Unitaid strategy 2010-2012
Key Performance Indicators 2010
Unitaid audited financial report for period 2008-2009
Key Performance Indicators 2009
Unitaid’s climate and health strategy 2023-2027
Unitaid’s investment case 2023-2027, executive summary
Unitaid’s investment case 2023-2027
Unitaid Strategy 2023-2027
Maternal and newborn health
Women’s and children’s health
Building for sustainability: Accelerating regional manufacturing for diagnostics (FIND and Unitaid)
Meeting report: Strengthening cooperation to enable sustainable development and manufacturing of effective, quality and affordable diagnostic countermeasures (FIND and Unitaid)
Q&A: Monoclonal antibodies
From milligrams to megatons: A climate and nature assessment of 10 key health products
Executive summary: From milligrams to megatons: A climate and nature assessment of 10 key health products
Landscape of rapid diagnostic tests for severe bacterial infections in advanced HIV Disease
The health products manufacturers support platform: Enhancing regional manufacturing of health technologies in Africa
Novel business models for accessible monoclonal antibodies for infectious diseases in LMICS: Multistakeholder meeting recommendations
Unitaid and the Government of Spain
About Unitaid (Saving lives faster)
Unitaid and the UK Government
Unitaid audited financial report for the year ended 31 December 2023
Partnership report: Unitaid and the Global Fund to Fight AIDS, Tuberculosis and Malaria
Unitaid audited financial report for the year ended 31 December 2022
ACT Forecasting Report Q1-2012
Key Performance Indicators 2012
HIV, Tuberculosis and Malaria medicines landscape
Unitaid audited financial report for the period 2010-2011
Malaria diagnostics technology landscape
HIV/AIDS diagnostics technology landscape – semi-annual update
HIV simple/rapid, EIA, and supplemental test market analysis
